AI주식인사이트AI Stock Insight
C

셀리드

299660KOSDAQ자연과학 및 공학 연구개발업

48.0 / 100

Reference Date: 2026-04-13

Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Declined 6.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellid is a biopharmaceutical company with proprietary technologies CeliVax (cancer immunotherapy vaccine) and Ad5/35 (infectious disease prevention vaccine), developing six cancer immunotherapy vaccines including BVAC-C and BVAC-E6E7, as well as a COVID-19 vaccine. It is currently conducting Phase 1/2a and 3 clinical trials, and generates revenue through CMO/CDMO services and e-commerce sales, though no products are currently on the market.

Number of Employees

49people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
0.97Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE
-19.25Industry Average -32.113.5Point

Below industry avg

Debt Ratio
9.75Industry Average 7.522.0Point

Higher than industry avg (caution)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲112.3% (1-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲3.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -27.6% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 2,450Won52-week high 8,89052-week low 2,315
1-month return2.0Point

1m -5.95% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0
  • Neutral주주명부폐쇄기간또는기준일설정2026-04-06
  • Neutral주주총회소집결의 (임시주주총회)2026-04-06
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral정기주주총회결과2026-03-31
  • Neutral[기재정정]신규시설투자등2026-03-30